Squamous Cell Carcinoma Pipeline 2025

DelveInsight's "Squamous Cell Carcinoma Pipeline Insight 2025" report offers extensive analysis on over 75 companies and more than 80 pipeline drugs in the Squamous Cell Carcinoma treatment arena. It features in-depth profiles of Squamous Cell Carcinoma pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses Squamous Cell Carcinoma therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Explore the thorough insights from DelveInsight and lead the way in grasping the Squamous Cell Carcinoma Treatment Landscape @ Squamous Cell Carcinoma Pipeline Outlook

Key Highlights from the Squamous Cell Carcinoma Pipeline Report

• On August 29, 2025, Merck Sharp & Dohme LLC launched a trial targeting esophageal squamous cell carcinoma (ESCC) that is locally advanced and inoperable—meaning it has infiltrated adjacent tissues and cannot be fully excised surgically—or metastatic, signifying spread to distant areas.

• On August 28, 2025, Fulgent Pharma LLC disclosed a FID-007 clinical trial to evaluate the effectiveness of various dosing schedules of FID-007 alongside Cetuximab in individuals with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The study seeks to assess effectiveness while profiling safety and tolerability. Participants will be assigned to one of two FID-007 groups, each paired with a consistent Cetuximab dose in 28-day intervals.

• On August 27, 2025, Regeneron Pharmaceuticals commenced a trial to test the experimental drug cemiplimab for managing early-stage cutaneous squamous cell carcinoma (CSCC), a form of skin malignancy. Cemiplimab boosts the immune system's capacity to destroy cancerous cells by attaching to a surface protein called programmed cell death-1 (PD-1) on certain immune cells.

• On August 20, 2025, Alentis Therapeutics AG started a trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and initial anti-cancer effects of ALE.P02 alone in adults with specific squamous solid tumors. The trial also intends to establish the recommended Phase II dose (RP2D).

• DelveInsight's Squamous Cell Carcinoma pipeline report showcases a dynamic field with over 75 active contributors developing more than 80 pipeline treatments for Squamous Cell Carcinoma care.

• The top Squamous Cell Carcinoma Companies include Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.

• Promising Squamous Cell Carcinoma Therapies include SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.

Acquire deep understanding of major Squamous Cell Carcinoma Clinical Trials and Emerging Drugs @ Squamous Cell Carcinoma Clinical Trials Assessment

Squamous Cell Carcinoma Emerging Drugs Profile

• NBTXR-3: Nanobiotix NBTXR3 is a groundbreaking, potentially pioneering oncology product made of functionalized hafnium oxide nanoparticles, delivered through a single intratumoral injection and triggered by radiation therapy. The drug is presently under Phase III clinical evaluation for treating patients with squamous cell carcinoma.

• mRNA-4157: Moderna Therapeutics mRNA-4157 is an experimental customized mRNA cancer vaccine, combined with Merck's anti-PD-1 therapy, for adjuvant care of patients with squamous cell carcinoma. The drug is currently in Phase II/III clinical trials for squamous cell carcinoma patients.

• HB-200: Hookipa Pharma HB-200 is HOOKIPA's primary oncology candidate built on their proprietary replicating arenaviral vector technology. HB-200 is a dual-vector immunotherapy aimed at directing immune responses against the encoded antigen. It includes two single-vector components with arenaviral frameworks derived from LCMV and PICV. Both produce and express an identical E7E6 fusion protein, containing recognized tumor-specific antigens for HPV16+ malignancies. The drug is undergoing Phase II clinical trials for squamous cell carcinoma patients.

• MCLA-158: Merus MCLA-158 (also called Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody that targets the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is engineered to demonstrate three distinct modes of action, including blocking EGFR-related signaling, LGR5 attachment causing EGFR uptake and breakdown in tumor cells, and improved antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis. The drug is in Phase I/II clinical trials for squamous cell carcinoma patients.

• HFB-301001: HiFiBiO HFB301001 is a novel fully human IgG1 class OX-40 stimulating antibody with an enhanced pharmacological profile. Unlike other anti-OX-40 antibodies, HFB301001's stimulating effect is amplified by the natural ligand OX-40L and avoids diminishing OX-40 levels on T cells. The drug is in Phase I clinical trials for squamous cell carcinoma patients.

The Squamous Cell Carcinoma Pipeline Report Provides Insights into

• The report delivers comprehensive details on firms advancing therapies for Squamous Cell Carcinoma, including the cumulative treatments each company is pursuing.

• It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for Squamous Cell Carcinoma management.

• Squamous Cell Carcinoma Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.

• Squamous Cell Carcinoma Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the Squamous Cell Carcinoma market.

Reveal essential updates on therapeutic breakthroughs and their implications for Squamous Cell Carcinoma Patients @ Squamous Cell Carcinoma Unmet Needs

Squamous Cell Carcinoma Companies and Therapies

• Sichuan Baili Pharmaceutical Co., Ltd.: SI-B001

• InflaRx GmbH: IFX-1

• Merck Sharp & Dohme LLC: MK-3475A

• ImmunityBio Inc.- Aldoxorubicin HCl

• Incyte Corporation: INCB099280

Squamous Cell Carcinoma pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration.

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Check out the newest developments in drug creation and clinical studies @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Squamous Cell Carcinoma Pipeline Report

• Coverage- Global

• Squamous Cell Carcinoma Companies- Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.

• Squamous Cell Carcinoma Therapies- SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.

• Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Obtain DelveInsight's detailed Squamous Cell Carcinoma pipeline report now! @ Squamous Cell Carcinoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction

2. Executive Summary

3. Squamous Cell Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Squamous Cell Carcinoma- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. NBTXR-3: Nanobiotix

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. HB-200: Hookipa Pharma

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. HFB-301001: HiFiBiO

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Squamous Cell Carcinoma Key Companies

21. Squamous Cell Carcinoma Key Products

22. Squamous Cell Carcinoma- Unmet Needs

23. Squamous Cell Carcinoma- Market Drivers and Barriers

24. Squamous Cell Carcinoma- Future Perspectives and Conclusion

25. Squamous Cell Carcinoma Analyst Views

26. Squamous Cell Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com